Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

Jiangnan Hu, Shengwei Huang, Lu Zhu, Weijie Huang, Yiping Zhao, Kunlin Jin, Qichuan Zhuge

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute ischemic stroke but concerns regarding its limitations remain. Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe 3 O 4 )-microrods (tPA-MRs) for targeted thrombolytic therapy in ischemic stroke induced by distal middle cerebral artery occlusion. We showed that intra-arterial injection of tPA-MRs could target the cerebral blood clot in vivo under the guidance of an external magnet, where tPA was subsequently released at the site of embolism. When applied with an external rotating magnetic field, rotating tPA-MRs significantly improved not only the mass transport of the tPA-clot reaction, but also mechanically disrupted the clot network, which thus increased clot interaction and penetration of tPA. Importantly, intravenously injected MRs could be discharged from the kidney, and the function of liver and kidney were not damaged at different durations after administration of tPA-MRs. Our data suggest that tPA-MRs overcome the limitations of thrombolytic therapy with tPA alone, which may be not only just for the treatment of ischemic stroke but also have majorly impact on other thrombotic diseases.

Original languageEnglish
Pages (from-to)32988-32997
Number of pages10
JournalACS Applied Materials and Interfaces
Volume10
Issue number39
DOIs
StatePublished - 3 Oct 2018

Fingerprint

Tissue Plasminogen Activator
Tissue
Fibrinolytic Agents
Iron oxides
Liver
Magnets
Blood
Mass transfer
Magnetic fields

Keywords

  • ischemia
  • microrods
  • stroke
  • thrombolysis
  • tissue plasminogen activator

Cite this

Hu, Jiangnan ; Huang, Shengwei ; Zhu, Lu ; Huang, Weijie ; Zhao, Yiping ; Jin, Kunlin ; Zhuge, Qichuan. / Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke. In: ACS Applied Materials and Interfaces. 2018 ; Vol. 10, No. 39. pp. 32988-32997.
@article{53fab9f0e7c8419f9a9572263e02939c,
title = "Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke",
abstract = "Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute ischemic stroke but concerns regarding its limitations remain. Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe 3 O 4 )-microrods (tPA-MRs) for targeted thrombolytic therapy in ischemic stroke induced by distal middle cerebral artery occlusion. We showed that intra-arterial injection of tPA-MRs could target the cerebral blood clot in vivo under the guidance of an external magnet, where tPA was subsequently released at the site of embolism. When applied with an external rotating magnetic field, rotating tPA-MRs significantly improved not only the mass transport of the tPA-clot reaction, but also mechanically disrupted the clot network, which thus increased clot interaction and penetration of tPA. Importantly, intravenously injected MRs could be discharged from the kidney, and the function of liver and kidney were not damaged at different durations after administration of tPA-MRs. Our data suggest that tPA-MRs overcome the limitations of thrombolytic therapy with tPA alone, which may be not only just for the treatment of ischemic stroke but also have majorly impact on other thrombotic diseases.",
keywords = "ischemia, microrods, stroke, thrombolysis, tissue plasminogen activator",
author = "Jiangnan Hu and Shengwei Huang and Lu Zhu and Weijie Huang and Yiping Zhao and Kunlin Jin and Qichuan Zhuge",
year = "2018",
month = "10",
day = "3",
doi = "10.1021/acsami.8b09423",
language = "English",
volume = "10",
pages = "32988--32997",
journal = "ACS Applied Materials and Interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "39",

}

Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke. / Hu, Jiangnan; Huang, Shengwei; Zhu, Lu; Huang, Weijie; Zhao, Yiping; Jin, Kunlin; Zhuge, Qichuan.

In: ACS Applied Materials and Interfaces, Vol. 10, No. 39, 03.10.2018, p. 32988-32997.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

AU - Hu, Jiangnan

AU - Huang, Shengwei

AU - Zhu, Lu

AU - Huang, Weijie

AU - Zhao, Yiping

AU - Jin, Kunlin

AU - Zhuge, Qichuan

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute ischemic stroke but concerns regarding its limitations remain. Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe 3 O 4 )-microrods (tPA-MRs) for targeted thrombolytic therapy in ischemic stroke induced by distal middle cerebral artery occlusion. We showed that intra-arterial injection of tPA-MRs could target the cerebral blood clot in vivo under the guidance of an external magnet, where tPA was subsequently released at the site of embolism. When applied with an external rotating magnetic field, rotating tPA-MRs significantly improved not only the mass transport of the tPA-clot reaction, but also mechanically disrupted the clot network, which thus increased clot interaction and penetration of tPA. Importantly, intravenously injected MRs could be discharged from the kidney, and the function of liver and kidney were not damaged at different durations after administration of tPA-MRs. Our data suggest that tPA-MRs overcome the limitations of thrombolytic therapy with tPA alone, which may be not only just for the treatment of ischemic stroke but also have majorly impact on other thrombotic diseases.

AB - Tissue plasminogen activator (tPA) is the only FDA approved thrombolytic drug for acute ischemic stroke but concerns regarding its limitations remain. Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe 3 O 4 )-microrods (tPA-MRs) for targeted thrombolytic therapy in ischemic stroke induced by distal middle cerebral artery occlusion. We showed that intra-arterial injection of tPA-MRs could target the cerebral blood clot in vivo under the guidance of an external magnet, where tPA was subsequently released at the site of embolism. When applied with an external rotating magnetic field, rotating tPA-MRs significantly improved not only the mass transport of the tPA-clot reaction, but also mechanically disrupted the clot network, which thus increased clot interaction and penetration of tPA. Importantly, intravenously injected MRs could be discharged from the kidney, and the function of liver and kidney were not damaged at different durations after administration of tPA-MRs. Our data suggest that tPA-MRs overcome the limitations of thrombolytic therapy with tPA alone, which may be not only just for the treatment of ischemic stroke but also have majorly impact on other thrombotic diseases.

KW - ischemia

KW - microrods

KW - stroke

KW - thrombolysis

KW - tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=85053895731&partnerID=8YFLogxK

U2 - 10.1021/acsami.8b09423

DO - 10.1021/acsami.8b09423

M3 - Article

VL - 10

SP - 32988

EP - 32997

JO - ACS Applied Materials and Interfaces

JF - ACS Applied Materials and Interfaces

SN - 1944-8244

IS - 39

ER -